Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Where
- China7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 12 people enrolled
- Started
- 14 Apr 2021
- Ended
- 20 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Rituximab
- cyclosporine
- Record updated
- 9 December 2025
- Why it stopped
- insufficient patient enrollment
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- idiopathic MN with or without diagnostic biopsy
- Female, must be post-menopausal, sterile or have effective method of contraception
- must be off steroid or mycophenolate mofetil for >1 month and alkylating agents for > 6 months
- Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for ≥3 months prior to randomization with controlled blood pressure or if patients is intolerant to ACEI/ARB
- proteinuria ≥4g/24h using the average from two 24-hour urine samples collected within 2 weeks of each other, and decreased ≤50% from baseline
- estimated glomerular filtration rate (eGFR) ≥40ml/min/1.73m2
Who cannot take part
- Patients who previously achieved remission after treatment of CNI, RTX or alkylating agents but relapsed off CNI after 3 months, or relapsed off RTX or alkylating agents after 6 months, are eligible
- presence of active infection or a secondary cause of MN
- diabetes mellitus: to exclude proteinuria secondary to diabetic nephropathy
- history of resistance to CsA or other calcineurin inhibitors(CNI), RTX or alkylating agents
- pregnancy or breast feeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this study is to determine whether or not cyclosporine (CsA) combined with RTX is more effective than RTX alone in the treatment of idiopathic membranous nephropathy (iMN).
The 2 groups in the trial
- Rituximab monotherapyExisting treatment, for comparison
Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to the CD19+ B cells count.
Treatment: Rituximab
- Rituximab combined with cyclosporineTreatment being tested
Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to CD19+ B cells count. cyclosporine (CsA) will be started at a dose of 3mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Doses of CsA will be adjusted according to the blood levels of CsA. CsA will be tapered after 6 months and discontinued over a 3 month period.
Treatment: Rituximab and cyclosporine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Randomized Controlled Trial of Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of Idiopathic Membranous Nephropathy
- Record updated
- 9 December 2025